Does route of administration affect the outcome of TNF antagonist therapy? View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2004-06-21

AUTHORS

Sergio Schwartzman, G James Morgan

ABSTRACT

The tumor necrosis factor (TNF) antagonists are parenterally administered biologic response modifiers indicated for the management of rheumatoid arthritis. Although infliximab, etanercept, and adalimumab are all members of this class, they differ in route of administration and dosing regimen. In the USA and in Europe, infliximab, in combination with oral methotrexate, is administered intravenously, initially at a dose of 3 mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter. The US Food and Drug Administration (FDA) has further approved that the dosage can be increased to 10 mg/kg and the doses can be given as often as every 4 weeks to optimize patient outcome (information based on the US package insert dated June 2002). Etanercept and adalimumab are given subcutaneously and can be self-injected. The FDA-approved dose of etanercept is 25 mg twice weekly, and of adalimumab is 40 mg every 2 weeks with methotrexate, or 40 mg alone. Medication adherence, possibly the most important factor in maintaining the benefits of anti-TNF therapy, is influenced by the interaction between the patient and his or her healthcare team, the patient's attitude toward the disease and medication regimen, and the choice of therapy. More... »

PAGES

s19-s23

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/ar996

DOI

http://dx.doi.org/10.1186/ar996

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1013531351

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15228617


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antirheumatic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arthritis, Rheumatoid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Routes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Necrosis Factor-alpha", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Hospital for Special Surgery, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.239915.5", 
          "name": [
            "Hospital for Special Surgery, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwartzman", 
        "givenName": "Sergio", 
        "id": "sg:person.014133305773.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014133305773.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA", 
          "id": "http://www.grid.ac/institutes/grid.413480.a", 
          "name": [
            "Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morgan", 
        "givenName": "G James", 
        "id": "sg:person.016267004752.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016267004752.30"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2004-06-21", 
    "datePublishedReg": "2004-06-21", 
    "description": "The tumor necrosis factor (TNF) antagonists are parenterally administered biologic response modifiers indicated for the management of rheumatoid arthritis. Although infliximab, etanercept, and adalimumab are all members of this class, they differ in route of administration and dosing regimen. In the USA and in Europe, infliximab, in combination with oral methotrexate, is administered intravenously, initially at a dose of 3 mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter. The US Food and Drug Administration (FDA) has further approved that the dosage can be increased to 10 mg/kg and the doses can be given as often as every 4 weeks to optimize patient outcome (information based on the US package insert dated June 2002). Etanercept and adalimumab are given subcutaneously and can be self-injected. The FDA-approved dose of etanercept is 25 mg twice weekly, and of adalimumab is 40 mg every 2 weeks with methotrexate, or 40 mg alone. Medication adherence, possibly the most important factor in maintaining the benefits of anti-TNF therapy, is influenced by the interaction between the patient and his or her healthcare team, the patient's attitude toward the disease and medication regimen, and the choice of therapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/ar996", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297499", 
        "issn": [
          "1478-6354", 
          "1478-6362"
        ], 
        "name": "Arthritis Research & Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "keywords": [
      "route of administration", 
      "tumor necrosis factor antagonists", 
      "anti-TNF therapy", 
      "dose of etanercept", 
      "TNF antagonist therapy", 
      "necrosis factor antagonists", 
      "biologic response modifiers", 
      "choice of therapy", 
      "oral methotrexate", 
      "medication regimen", 
      "antagonist therapy", 
      "rheumatoid arthritis", 
      "medication adherence", 
      "weeks 0", 
      "patients' attitudes", 
      "patient outcomes", 
      "factor antagonists", 
      "response modifiers", 
      "US Food", 
      "Drug Administration", 
      "healthcare team", 
      "etanercept", 
      "adalimumab", 
      "therapy", 
      "administration", 
      "weeks", 
      "infliximab", 
      "regimen", 
      "methotrexate", 
      "dose", 
      "outcomes", 
      "arthritis", 
      "patients", 
      "antagonist", 
      "doses", 
      "disease", 
      "adherence", 
      "FDA", 
      "dosage", 
      "important factor", 
      "management", 
      "food", 
      "factors", 
      "benefits", 
      "team", 
      "attitudes", 
      "route", 
      "combination", 
      "modifiers", 
      "members", 
      "choice", 
      "USA", 
      "interaction", 
      "Europe", 
      "class"
    ], 
    "name": "Does route of administration affect the outcome of TNF antagonist therapy?", 
    "pagination": "s19-s23", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1013531351"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/ar996"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15228617"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/ar996", 
      "https://app.dimensions.ai/details/publication/pub.1013531351"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_394.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/ar996"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/ar996'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/ar996'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/ar996'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/ar996'


 

This table displays all metadata directly associated to this object as RDF triples.

151 TRIPLES      21 PREDICATES      87 URIs      79 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/ar996 schema:about N222274134e234059a8619c6be4a7846a
2 N4be35973c5c34ae9a63ab48c1fc013c3
3 N74285ca11f654421829476c0df435e9d
4 Nb38c8e1845dc40f09110cb65070bed63
5 Nf2a6515849894cdf9ffe02552474bc21
6 Nf8d43f91d4ef4bb5acd3e6bb2a8c1327
7 anzsrc-for:11
8 anzsrc-for:1115
9 schema:author Nfebcdb0f71fe41798191a59ce03ee688
10 schema:datePublished 2004-06-21
11 schema:datePublishedReg 2004-06-21
12 schema:description The tumor necrosis factor (TNF) antagonists are parenterally administered biologic response modifiers indicated for the management of rheumatoid arthritis. Although infliximab, etanercept, and adalimumab are all members of this class, they differ in route of administration and dosing regimen. In the USA and in Europe, infliximab, in combination with oral methotrexate, is administered intravenously, initially at a dose of 3 mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter. The US Food and Drug Administration (FDA) has further approved that the dosage can be increased to 10 mg/kg and the doses can be given as often as every 4 weeks to optimize patient outcome (information based on the US package insert dated June 2002). Etanercept and adalimumab are given subcutaneously and can be self-injected. The FDA-approved dose of etanercept is 25 mg twice weekly, and of adalimumab is 40 mg every 2 weeks with methotrexate, or 40 mg alone. Medication adherence, possibly the most important factor in maintaining the benefits of anti-TNF therapy, is influenced by the interaction between the patient and his or her healthcare team, the patient's attitude toward the disease and medication regimen, and the choice of therapy.
13 schema:genre article
14 schema:inLanguage en
15 schema:isAccessibleForFree true
16 schema:isPartOf N9f31945f49b048c783b248b3340b2842
17 Nefb6ad91eca442649d7c94daebf8d12f
18 sg:journal.1297499
19 schema:keywords Drug Administration
20 Europe
21 FDA
22 TNF antagonist therapy
23 US Food
24 USA
25 adalimumab
26 adherence
27 administration
28 antagonist
29 antagonist therapy
30 anti-TNF therapy
31 arthritis
32 attitudes
33 benefits
34 biologic response modifiers
35 choice
36 choice of therapy
37 class
38 combination
39 disease
40 dosage
41 dose
42 dose of etanercept
43 doses
44 etanercept
45 factor antagonists
46 factors
47 food
48 healthcare team
49 important factor
50 infliximab
51 interaction
52 management
53 medication adherence
54 medication regimen
55 members
56 methotrexate
57 modifiers
58 necrosis factor antagonists
59 oral methotrexate
60 outcomes
61 patient outcomes
62 patients
63 patients' attitudes
64 regimen
65 response modifiers
66 rheumatoid arthritis
67 route
68 route of administration
69 team
70 therapy
71 tumor necrosis factor antagonists
72 weeks
73 weeks 0
74 schema:name Does route of administration affect the outcome of TNF antagonist therapy?
75 schema:pagination s19-s23
76 schema:productId N04bae45335324252940624ce03e09257
77 N2244f436d3404653b4a96de404483419
78 N316f07e37e1b4793b7d737b5f80efbc8
79 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013531351
80 https://doi.org/10.1186/ar996
81 schema:sdDatePublished 2022-01-01T18:14
82 schema:sdLicense https://scigraph.springernature.com/explorer/license/
83 schema:sdPublisher N0d88f9b1bcbb4e4ab1af9d7fa1258ada
84 schema:url https://doi.org/10.1186/ar996
85 sgo:license sg:explorer/license/
86 sgo:sdDataset articles
87 rdf:type schema:ScholarlyArticle
88 N01923bb2ec824785b8ffdd3a83450230 rdf:first sg:person.016267004752.30
89 rdf:rest rdf:nil
90 N04bae45335324252940624ce03e09257 schema:name dimensions_id
91 schema:value pub.1013531351
92 rdf:type schema:PropertyValue
93 N0d88f9b1bcbb4e4ab1af9d7fa1258ada schema:name Springer Nature - SN SciGraph project
94 rdf:type schema:Organization
95 N222274134e234059a8619c6be4a7846a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Drug Administration Routes
97 rdf:type schema:DefinedTerm
98 N2244f436d3404653b4a96de404483419 schema:name doi
99 schema:value 10.1186/ar996
100 rdf:type schema:PropertyValue
101 N316f07e37e1b4793b7d737b5f80efbc8 schema:name pubmed_id
102 schema:value 15228617
103 rdf:type schema:PropertyValue
104 N4be35973c5c34ae9a63ab48c1fc013c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Antirheumatic Agents
106 rdf:type schema:DefinedTerm
107 N74285ca11f654421829476c0df435e9d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Humans
109 rdf:type schema:DefinedTerm
110 N9f31945f49b048c783b248b3340b2842 schema:issueNumber Suppl 2
111 rdf:type schema:PublicationIssue
112 Nb38c8e1845dc40f09110cb65070bed63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Tumor Necrosis Factor-alpha
114 rdf:type schema:DefinedTerm
115 Nefb6ad91eca442649d7c94daebf8d12f schema:volumeNumber 6
116 rdf:type schema:PublicationVolume
117 Nf2a6515849894cdf9ffe02552474bc21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Treatment Outcome
119 rdf:type schema:DefinedTerm
120 Nf8d43f91d4ef4bb5acd3e6bb2a8c1327 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Arthritis, Rheumatoid
122 rdf:type schema:DefinedTerm
123 Nfebcdb0f71fe41798191a59ce03ee688 rdf:first sg:person.014133305773.18
124 rdf:rest N01923bb2ec824785b8ffdd3a83450230
125 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
126 schema:name Medical and Health Sciences
127 rdf:type schema:DefinedTerm
128 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
129 schema:name Pharmacology and Pharmaceutical Sciences
130 rdf:type schema:DefinedTerm
131 sg:journal.1297499 schema:issn 1478-6354
132 1478-6362
133 schema:name Arthritis Research & Therapy
134 schema:publisher Springer Nature
135 rdf:type schema:Periodical
136 sg:person.014133305773.18 schema:affiliation grid-institutes:grid.239915.5
137 schema:familyName Schwartzman
138 schema:givenName Sergio
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014133305773.18
140 rdf:type schema:Person
141 sg:person.016267004752.30 schema:affiliation grid-institutes:grid.413480.a
142 schema:familyName Morgan
143 schema:givenName G James
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016267004752.30
145 rdf:type schema:Person
146 grid-institutes:grid.239915.5 schema:alternateName Hospital for Special Surgery, New York, NY, USA
147 schema:name Hospital for Special Surgery, New York, NY, USA
148 rdf:type schema:Organization
149 grid-institutes:grid.413480.a schema:alternateName Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
150 schema:name Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
151 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...